Letter to the Editor
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jul 15, 2025; 17(7): 105034
Published online Jul 15, 2025. doi: 10.4251/wjgo.v17.i7.105034
Resveratrol: A promising agent in targeting senescent cancer-associated fibroblasts to inhibit pancreatic cancer progression
Hao Qin
Hao Qin, State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
Author contributions: Qin H was responsible for the study’s conception, manuscript writing and editing, and final approval.
Supported by National Natural Science Foundation of China, No. 82304151.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hao Qin, PhD, State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China. haoqin@bjmu.edu.cn
Received: January 10, 2025
Revised: February 19, 2025
Accepted: February 26, 2025
Published online: July 15, 2025
Processing time: 185 Days and 19.3 Hours
Core Tip

Core Tip: Pancreatic cancer remains a challenging disease with limited treatment options, largely due to the tumor microenvironment (TME) and its cancer-associated fibroblasts (CAFs). Senescent CAFs, through their senescence-associated secretory phenotype (SASP), contribute to tumor progression. Recent studies have explored the potential of resveratrol, a natural polyphenolic compound, to target these senescent CAFs. Resveratrol reduces the number of senescent CAFs, downregulates SASP factors, and disrupts tumor-promoting interactions in the TME. These findings suggest that resveratrol could serve as an effective adjunctive therapy for pancreatic cancer by modulating the TME and inhibiting cancer cell proliferation and metastasis.